Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Subjects With Cystic Fibrosis (CF)

This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.

forced expiratory volume
tezacaftor
ivacaftor
fibrosis
elexacaftor
  • 0 views
  • 17 Mar, 2022
  • 16 locations
Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)

Trikafta™. Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del

fibrosis
tezacaftor
ivacaftor
elexacaftor
pulmozyme
  • 65 views
  • 02 May, 2022
  • 78 locations
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

The purpose of this pilot study is to explore wither ivacaftor in refractory CRS patients will demonstrate safety and tolerability; restore CFTR-mediated Cl- secretions as measured by EDSPD

rhinosinusitis
ct scan
ivacaftor
cavities
  • 6 views
  • 26 Feb, 2022
  • 1 location
Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.

  • 0 views
  • 01 Oct, 2021
  • 1 location
The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor

The study is a Phase 2 Study to establish the safety and efficacy of a drug called Ivacaftor (VX-770) in patients with chronic obstructive pulmonary disease (COPD), chronic bronchitis, and

copd exacerbation
bronchodilator
sweat chloride
a 10
COPD
  • 140 views
  • 09 Apr, 2022
  • 1 location
Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi .

The purpose of the study is to investigate whether the correction of CFTR function by Lumacaftor/Ivacaftor in a patient-derived primary nasal cell model is a surrogate biomarker for respiratory

orkambi
ivacaftor
lumacaftor
diagnostic procedures
  • 0 views
  • 30 Sep, 2021
  • 1 location
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

This is a Phase 2 open-label, dose-escalation study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with

fibrosis
ivacaftor
body mass index
  • 45 views
  • 25 Mar, 2022
  • 8 locations
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with CF with at least

nonsense mutation
fibrosis
cftr modulators
ivacaftor
body mass index
  • 1 views
  • 10 Mar, 2022
  • 6 locations
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) (RECOVER)

RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor, tezacaftor and ivacaftor triple combination therapy (Kaftrio

spirometry
tezacaftor
ivacaftor
fibrosis
elexacaftor
  • 52 views
  • 18 May, 2022
  • 7 locations
Personalized Theratyping Trial

The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.

cftr modulators
  • 1 views
  • 01 Oct, 2021
  • 1 location